Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic screening the novel targets of sericin in human hepatocellular carcinoma cells

ABSTRACT: Transcriptomic screening the novel targets of sericin in human hepatocellular carcinoma cells

PROVIDER: PRJNA952692 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24087584_1.fastq.gz	Fastqsanger.gz
	SRR24087584_2.fastq.gz	Fastqsanger.gz
	SRR24087585_1.fastq.gz	Fastqsanger.gz
	SRR24087585_2.fastq.gz	Fastqsanger.gz
	SRR24087586_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Transcriptomic screening the novel targets of sericin in human hepatocellular carcinoma cells

Project description:To investigate the possible novel targets of sericin on human hepatocellular carcinoma cells and related cellular pathways

2024-03-13 | GSE229079 | GEO

Transcriptomics-based Screening and Novel compound for Hepatocellular Carcinoma

Project description:Transcriptomics-based Screening and Novel compound for Hepatocellular Carcinoma

| PRJNA1235598 | ENA

The novel protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment

Project description:Metabolic reprogramming fuels cancer cell metastasis and remodels the immunosuppressive tumor microenvironment (TME). We report here that a circRNA, circPETH, packaged by extracellular vesicles (EVs) from tumor-associated macrophages (TAMs) to hepatocellular carcinoma (HCC) cells, facilitates glycolysis and metastasis of recipient HCC cells. Mechanistically, circPETH-147aa, encoded by circPETH in a m6A-driven manner, promotes PKM2-catalyzed ALDOA-S36 phosphorylation via MEG pocket. Furthermore, circPETH-147aa impairs anti-HCC immunity by elevating HuR-dependent SLC43A2 mRNA stability and driving methionine and leucine deficiency in cytotoxic CD8+ T cells. Importantly, by virtual and experimental screening, we found that the novel small-molecule Norathyriol was an effective inhibitor that targets the MEG pocket on circPETH-147aa surface. Norathyriol reverses circPETH-147aa-facilitated acquisition of metabolic and metastatic phenotypes by HCC cells, increases anti-PD1 efficacy and boosts cytotoxic CD8+ T-cell function. Our findings determine Norathyriol as a promising anti-HCC agent that contributes to the attenuation of advanced HCC resistance to immune checkpoint blocker (ICB) therapies.

2024-12-09 | MTBLS11254 | MetaboLights

hepatocellular carcinoma vs. corresponding noncancerous liver or normal liver

Project description:Hepatocellular carcinoma (HCC) remains a major health problem worldwide, and HCC patients have a poor prognostic outcome. In this study, we systematically disclose mechanisms of hepatocarcinogenesis, and also effectively identify and validate novel anticancer targets in HCCs. Keywords: disease state analysis total 58 cDNA microarrays, all experiment samples are hepatocellular carcinoma. RNAs from 33 corresponding noncancerous livers and 5 normal livers were used as the reference, respectively. The tumor samples were labeled with Cy5-dUTP.The nontumor samples were labeled with Cy3-dUTP.

2009-01-06 | E-GEOD-4108 | biostudies-arrayexpress

A CRISPR/Cas9 library screening identified CARM1 as a critical inhibitor for Sorafenib-induced ferroptosis in hepatocellular carcinoma cells [CRISPR screen]

Project description:To find epigenetic factors potentially involved in Sorafenib resistance in hepatocellular carcinoma cells, an epigenetic factors-targeted CRISPR/Cas9 library was applied to perform the screening.

2023-01-01 | GSE215909 | GEO

Evaluation the targeted nanobubbles mediated LND against hepatocellular carcinoma by sonodynamic therapy with RNA-Seq

Project description:Sonodynamic therapy is an important approach in the treatment of hepatocellular carcinoma. A novel targeted nanobubbles loaded with HMME and LND was structured as sensibilizer, characterized the properties, and studied therapeutic effect on hepatocellular carcinoma. Next-generation high throughput RNA sequencing (RNA-Seq) was performed to accurately analyze the differential expression of mRNAs and lncRNA targets in hepatocellular carcinoma after sonodynamic therapy.

2022-03-02 | GSE171857 | GEO

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

Project description:Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

| PRJNA1063443 | ENA

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

Project description:Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

| PRJNA1063444 | ENA

Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma

Project description:Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma

| PRJNA445291 | ENA

hepatocellular carcinoma vs. corresponding noncancerous liver or normal liver

2009-01-06 | GSE4108 | GEO